Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
IKTInhibikase Therapeutics(IKT) GlobeNewswire News Room·2024-06-05 20:05
  • Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced expansion of its therapeutic pipeline and multiple ...